NO312995B1 - Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom - Google Patents

Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom Download PDF

Info

Publication number: NO312995B1
Authority: NO; Norway
Prior art keywords: methyl; fluorophenyl; compound; pyrimidine; alkyl
Prior art date: 1994-09-09

Application number

NO19971050A

Other languages

English (en)

Norwegian (no)

Other versions

NO971050D0 (no

NO971050L (no

Inventor

Shoichi Chokai

Yojiro Ukai

Tomiyoshi Aoki

Kyoichi Ideguchi

Original Assignee

Nippon Shinyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-09

Filing date

1997-03-07

Publication date

2002-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16685068&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO312995(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-07 Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd

1997-03-07 Publication of NO971050D0 publication Critical patent/NO971050D0/no

1997-05-09 Publication of NO971050L publication Critical patent/NO971050L/no

2002-07-29 Publication of NO312995B1 publication Critical patent/NO312995B1/no

Links

208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 29
238000004519 manufacturing process Methods 0.000 title claims description 3
239000003814 drug Substances 0.000 title description 16
229940079593 drug Drugs 0.000 title description 11
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
150000003222 pyridines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 100
230000016273 neuron death Effects 0.000 claims abstract description 21
150000003839 salts Chemical class 0.000 claims abstract description 18
125000000217 alkyl group Chemical group 0.000 claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
230000002401 inhibitory effect Effects 0.000 claims abstract description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 13
125000002947 alkylene group Chemical group 0.000 claims description 11
239000012453 solvate Substances 0.000 claims description 11
210000004556 brain Anatomy 0.000 claims description 10
125000005843 halogen group Chemical group 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
ORTUSOZFGJTTMI-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-methyl-6-(4-piperidin-1-ylbutoxy)pyrimidine Chemical compound N=1C(C=2C=CC(F)=CC=2)=NC(C)=CC=1OCCCCN1CCCCC1 ORTUSOZFGJTTMI-UHFFFAOYSA-N 0.000 claims description 3
FZZSHCIWMDTHKB-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(4-piperidin-1-ylbutoxy)pyrimidine Chemical compound C=1C(C=2C=CC(F)=CC=2)=NC(C)=NC=1OCCCCN1CCCCC1 FZZSHCIWMDTHKB-UHFFFAOYSA-N 0.000 claims description 3
OAELLVUITMSTBN-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentan-2-yloxy)pyrimidine Chemical compound C=1C(C=2C=CC(F)=CC=2)=NC(C)=NC=1OC(C)CCCN1CCCCC1 OAELLVUITMSTBN-UHFFFAOYSA-N 0.000 claims description 3
PUYGGMIXGXNYFR-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(6-piperidin-1-ylhexoxy)pyrimidine Chemical compound C=1C(C=2C=CC(F)=CC=2)=NC(C)=NC=1OCCCCCCN1CCCCC1 PUYGGMIXGXNYFR-UHFFFAOYSA-N 0.000 claims description 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
XJUJSZXMVWAXCP-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(3-piperidin-1-ylpropoxy)pyridine Chemical compound N=1C(C)=CC(C=2C=CC(F)=CC=2)=CC=1OCCCN1CCCCC1 XJUJSZXMVWAXCP-UHFFFAOYSA-N 0.000 claims description 2
LKYPFVJBVDQZJD-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyridine Chemical compound N=1C(C)=CC(C=2C=CC(F)=CC=2)=CC=1OCCCCCN1CCCCC1 LKYPFVJBVDQZJD-UHFFFAOYSA-N 0.000 claims description 2
SZSHJTJCJOWMHM-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-(5-piperidin-1-ylpentoxy)pyrimidine Chemical compound C=1C(C=2C=CC(F)=CC=2)=NC(C)=NC=1OCCCCCN1CCCCC1 SZSHJTJCJOWMHM-UHFFFAOYSA-N 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
125000003386 piperidinyl group Chemical group 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
229940126585 therapeutic drug Drugs 0.000 abstract description 5
125000003342 alkenyl group Chemical group 0.000 abstract description 2
229910052760 oxygen Inorganic materials 0.000 abstract description 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000006681 (C2-C10) alkylene group Chemical group 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000004663 dialkyl amino group Chemical group 0.000 abstract 1
125000001188 haloalkyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 description 43
238000000921 elemental analysis Methods 0.000 description 37
239000013078 crystal Substances 0.000 description 29
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 20
239000002904 solvent Substances 0.000 description 20
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000002585 base Substances 0.000 description 18
239000000243 solution Substances 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 16
239000000843 powder Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
239000005457 ice water Substances 0.000 description 12
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
150000004820 halides Chemical class 0.000 description 11
238000000034 method Methods 0.000 description 11
206010008118 cerebral infarction Diseases 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
229910000104 sodium hydride Inorganic materials 0.000 description 10
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000002569 neuron Anatomy 0.000 description 9
-1 N , N-dimethylamino Chemical group 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
229910000041 hydrogen chloride Inorganic materials 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
230000003111 delayed effect Effects 0.000 description 7
238000001914 filtration Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
208000028867 ischemia Diseases 0.000 description 7
238000010898 silica gel chromatography Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
230000034994 death Effects 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
239000012312 sodium hydride Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
230000002490 cerebral effect Effects 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
230000000302 ischemic effect Effects 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 5
239000007787 solid Substances 0.000 description 5
ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
OXPDQFOKSZYEMJ-UHFFFAOYSA-N 2-phenylpyrimidine Chemical class C1=CC=CC=C1C1=NC=CC=N1 OXPDQFOKSZYEMJ-UHFFFAOYSA-N 0.000 description 4
201000006474 Brain Ischemia Diseases 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
239000007810 chemical reaction solvent Substances 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
229930195712 glutamate Natural products 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000002798 polar solvent Substances 0.000 description 4
239000000376 reactant Substances 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 4
229910001958 silver carbonate Inorganic materials 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
239000008096 xylene Substances 0.000 description 4
ZNUQLGRLMDQIID-BTJKTKAUSA-N (Z)-but-2-enedioic acid pyrimidine Chemical compound C1=CN=CN=C1.OC(=O)\C=C/C(O)=O ZNUQLGRLMDQIID-BTJKTKAUSA-N 0.000 description 3
YACHMEHMACAROB-UHFFFAOYSA-N 6-(4-fluorophenyl)-2-methyl-1h-pyrimidin-4-one Chemical compound CC1=NC(O)=CC(C=2C=CC(F)=CC=2)=N1 YACHMEHMACAROB-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000020358 Learning disease Diseases 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 3
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
230000036461 convulsion Effects 0.000 description 3
230000002461 excitatory amino acid Effects 0.000 description 3
239000003257 excitatory amino acid Substances 0.000 description 3
230000007574 infarction Effects 0.000 description 3
201000003723 learning disability Diseases 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
YYXKRNUJMKSJMF-UHFFFAOYSA-N (4-phenylmethoxybenzenecarboximidoyl)azanium;chloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1OCC1=CC=CC=C1 YYXKRNUJMKSJMF-UHFFFAOYSA-N 0.000 description 2
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
AMEVJOWOWQPPJQ-UHFFFAOYSA-N 2,4-dichloro-6-phenyl-1,3,5-triazine Chemical compound ClC1=NC(Cl)=NC(C=2C=CC=CC=2)=N1 AMEVJOWOWQPPJQ-UHFFFAOYSA-N 0.000 description 2
OXACGAZCPDGFFW-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-methyl-6-pent-4-enylpyrimidine Chemical compound CC1=NC(CCCC=C)=CC(C=2C=CC(F)=CC=2)=N1 OXACGAZCPDGFFW-UHFFFAOYSA-N 0.000 description 2
CMHKVLZZLUCNGV-UHFFFAOYSA-N 4-chloro-6-(4-fluorophenyl)-2-methylpyrimidine Chemical compound CC1=NC(Cl)=CC(C=2C=CC(F)=CC=2)=N1 CMHKVLZZLUCNGV-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
206010008089 Cerebral artery occlusion Diseases 0.000 description 2
206010008111 Cerebral haemorrhage Diseases 0.000 description 2
206010008120 Cerebral ischaemia Diseases 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241000699694 Gerbillinae Species 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000000219 Sympatholytic Substances 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
210000003323 beak Anatomy 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
210000001168 carotid artery common Anatomy 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
SJUXLKYJKQBZLM-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=C(F)C=C1 SJUXLKYJKQBZLM-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000011068 loading method Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002609 medium Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
GEFZIAWNHFKQDM-UHFFFAOYSA-N 1-(4-fluorophenyl)butane-1,3-dione Chemical compound CC(=O)CC(=O)C1=CC=C(F)C=C1 GEFZIAWNHFKQDM-UHFFFAOYSA-N 0.000 description 1
ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
PBSOXYIHMPMWID-UHFFFAOYSA-N 2-(4-fluorophenyl)-6-methyl-1h-pyridin-4-one Chemical compound CC1=CC(O)=CC(C=2C=CC(F)=CC=2)=N1 PBSOXYIHMPMWID-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
MZHFNHGPRUIATC-UHFFFAOYSA-N 2-chloro-4-methyl-6-phenyl-1,3,5-triazine Chemical compound CC1=NC(Cl)=NC(C=2C=CC=CC=2)=N1 MZHFNHGPRUIATC-UHFFFAOYSA-N 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
RVIMLLPOUBGWDZ-UHFFFAOYSA-N 4,6-bis(4-fluorophenoxy)-2-methylpyrimidine Chemical compound C=1C(OC=2C=CC(F)=CC=2)=NC(C)=NC=1OC1=CC=C(F)C=C1 RVIMLLPOUBGWDZ-UHFFFAOYSA-N 0.000 description 1
GGZQCZHQRUMNPL-UHFFFAOYSA-N 4,6-bis[(4-fluorophenyl)sulfanyl]-2-methylpyrimidine Chemical compound C=1C(SC=2C=CC(F)=CC=2)=NC(C)=NC=1SC1=CC=C(F)C=C1 GGZQCZHQRUMNPL-UHFFFAOYSA-N 0.000 description 1
FIMUTBLUWQGTIJ-UHFFFAOYSA-N 4,6-dichloro-2-methylpyrimidine Chemical compound CC1=NC(Cl)=CC(Cl)=N1 FIMUTBLUWQGTIJ-UHFFFAOYSA-N 0.000 description 1
CDMRIJOEWSDGFS-UHFFFAOYSA-N 4-(4-fluorophenyl)-6-methyl-1h-pyrimidin-2-one Chemical compound OC1=NC(C)=CC(C=2C=CC(F)=CC=2)=N1 CDMRIJOEWSDGFS-UHFFFAOYSA-N 0.000 description 1
AFYALJSDFPSAAZ-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1CCNCC1 AFYALJSDFPSAAZ-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
XNCLRGKBECDKIO-UHFFFAOYSA-N 4-chloro-6-(2,4-dichlorophenyl)-2-methylpyrimidine Chemical compound CC1=NC(Cl)=CC(C=2C(=CC(Cl)=CC=2)Cl)=N1 XNCLRGKBECDKIO-UHFFFAOYSA-N 0.000 description 1
CEFACUXKVSXFHZ-UHFFFAOYSA-N 4-chloro-6-(2-chlorophenyl)-2-methylpyrimidine Chemical compound CC1=NC(Cl)=CC(C=2C(=CC=CC=2)Cl)=N1 CEFACUXKVSXFHZ-UHFFFAOYSA-N 0.000 description 1
DICBSGUAJDDNPC-UHFFFAOYSA-N 4-chloro-6-(2-fluorophenyl)-5-methylpyrimidine Chemical compound CC1=C(Cl)N=CN=C1C1=CC=CC=C1F DICBSGUAJDDNPC-UHFFFAOYSA-N 0.000 description 1
GOIVJOURAIMNHX-UHFFFAOYSA-N 4-chloro-6-(4-fluorophenyl)-2,5-dimethylpyrimidine Chemical compound CC1=NC(Cl)=C(C)C(C=2C=CC(F)=CC=2)=N1 GOIVJOURAIMNHX-UHFFFAOYSA-N 0.000 description 1
OLWZFCDIWDPDBZ-UHFFFAOYSA-N 4-chloro-6-methyl-2-(4-phenylmethoxyphenyl)pyrimidine Chemical compound CC1=CC(Cl)=NC(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 OLWZFCDIWDPDBZ-UHFFFAOYSA-N 0.000 description 1
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
125000006042 4-hexenyl group Chemical group 0.000 description 1
RJBSTXIIQYFNPX-UHFFFAOYSA-N 4-methoxy-6-phenyl-1,3,5-triazin-2-amine Chemical compound COC1=NC(N)=NC(C=2C=CC=CC=2)=N1 RJBSTXIIQYFNPX-UHFFFAOYSA-N 0.000 description 1
FVNXVWGSDCWKSN-UHFFFAOYSA-N 4-methyl-2-phenyl-6-[2-(4-phenylpiperazin-1-yl)ethoxy]pyrimidine Chemical compound N=1C(C=2C=CC=CC=2)=NC(C)=CC=1OCCN(CC1)CCN1C1=CC=CC=C1 FVNXVWGSDCWKSN-UHFFFAOYSA-N 0.000 description 1
UDAOJHAASAWVIQ-UHFFFAOYSA-N 4-phenylmethoxybenzonitrile Chemical compound C1=CC(C#N)=CC=C1OCC1=CC=CC=C1 UDAOJHAASAWVIQ-UHFFFAOYSA-N 0.000 description 1
WKJFILILEWPMQF-UHFFFAOYSA-N 5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC(Cl)=CC(Cl)=C1Cl WKJFILILEWPMQF-UHFFFAOYSA-N 0.000 description 1
BVWVBAFKSRBVDR-UHFFFAOYSA-N 5-(2-chlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC=CC=C1Cl BVWVBAFKSRBVDR-UHFFFAOYSA-N 0.000 description 1
LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
XSDJBRKQLXWBCS-UHFFFAOYSA-N 6-(4-fluorophenyl)-2,5-dimethyl-1h-pyrimidin-4-one Chemical compound CC1=NC(O)=C(C)C(C=2C=CC(F)=CC=2)=N1 XSDJBRKQLXWBCS-UHFFFAOYSA-N 0.000 description 1
AJJRCMDWYCMGSE-UHFFFAOYSA-N 6-(4-fluorophenyl)-5-methyl-1h-pyrimidin-4-one Chemical compound CC1=C(O)N=CN=C1C1=CC=C(F)C=C1 AJJRCMDWYCMGSE-UHFFFAOYSA-N 0.000 description 1
DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
SKTDQCNRPQSDFG-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)C1=NC(=NC(=C1)O)C.ClC1=C(C=CC=C1)C1=NC(=NC(=C1)O)C Chemical compound ClC1=C(C=CC(=C1)Cl)C1=NC(=NC(=C1)O)C.ClC1=C(C=CC=C1)C1=NC(=NC(=C1)O)C SKTDQCNRPQSDFG-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000018899 Glutamate Receptors Human genes 0.000 description 1
108010027915 Glutamate Receptors Proteins 0.000 description 1
229940122459 Glutamate antagonist Drugs 0.000 description 1
229940086575 Glutamate release inhibitor Drugs 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
UULYVBBLIYLRCU-UHFFFAOYSA-N Palmitinsaeure-n-tetradecylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC UULYVBBLIYLRCU-UHFFFAOYSA-N 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
108010035235 Phleomycins Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
OFJJGSAYWPNTEW-UHFFFAOYSA-M [Br-].C1CCOC1.[Mg+]C1=CC=CC=C1 Chemical compound [Br-].C1CCOC1.[Mg+]C1=CC=CC=C1 OFJJGSAYWPNTEW-UHFFFAOYSA-M 0.000 description 1
VHHPDZDTKZOHTB-UHFFFAOYSA-M [Br-].[Mg+]C.C1CCOC1 Chemical compound [Br-].[Mg+]C.C1CCOC1 VHHPDZDTKZOHTB-UHFFFAOYSA-M 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000010531 catalytic reduction reaction Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
210000000883 ear external Anatomy 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000011556 gerbil model Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000002307 glutamic acids Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
UMLFDVOHVJPDIZ-UHFFFAOYSA-N hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride Chemical compound Cl.[O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CN=C1 UMLFDVOHVJPDIZ-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000010410 layer Substances 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
201000007309 middle cerebral artery infarction Diseases 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
VHFXKCTYULMJQQ-UHFFFAOYSA-N n,n-dimethyl-2-(4-thiophen-2-ylpyrimidin-2-yl)oxyethanamine Chemical class CN(C)CCOC1=NC=CC(C=2SC=CC=2)=N1 VHFXKCTYULMJQQ-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
210000000956 olfactory bulb Anatomy 0.000 description 1
210000000196 olfactory nerve Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
229960002934 propentofylline Drugs 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
210000002763 pyramidal cell Anatomy 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000004895 regional blood flow Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000009491 slugging Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
210000000216 zygoma Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Steroid Compounds (AREA)

NO19971050A 1994-09-09 1997-03-07 Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom NO312995B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP21621494		1994-09-09
PCT/JP1995/001792 WO1996007641A1 (fr)	1994-09-09	1995-09-08	Derive heterocyclique et medicament

Publications (3)

Publication Number	Publication Date
NO971050D0 NO971050D0 (no)	1997-03-07
NO971050L NO971050L (no)	1997-05-09
NO312995B1 true NO312995B1 (no)	2002-07-29

Family

ID=16685068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971050A NO312995B1 (no)	1994-09-09	1997-03-07	Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom

Country Status (19)

Country	Link
US (2)	US5945426A (de)
EP (1)	EP0781766B1 (de)
JP (2)	JP3036079B2 (de)
KR (1)	KR100358245B1 (de)
CN (1)	CN1118454C (de)
AT (1)	ATE263154T1 (de)
BR (1)	BR9508900A (de)
CA (1)	CA2199518A1 (de)
DE (1)	DE69532811T2 (de)
DK (1)	DK0781766T3 (de)
ES (1)	ES2218552T3 (de)
FI (1)	FI970967A (de)
HU (1)	HU221855B1 (de)
MX (1)	MX9701765A (de)
NO (1)	NO312995B1 (de)
NZ (1)	NZ292269A (de)
PT (1)	PT781766E (de)
RU (1)	RU2128996C1 (de)
WO (1)	WO1996007641A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1300056B1 (it) *	1998-04-17	2000-04-05	Boehringer Ingelheim Italia	Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
EP1108430A1 (de) *	1998-08-25	2001-06-20	Nippon Shinyaku Co., Ltd.	Kalzium-kanal antagonisten
US20040077709A1 (en) *	1999-05-31	2004-04-22	Daiichi Pharmaceutical Co., Ltd.	Neuronal death inhibitors
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
EP1318146B1 (de) *	2000-09-08	2005-02-23	Nippon Shinyaku Co., Ltd.	Verfahren zur produktion von pyrimidinderivaten und geeignete zwischenprodukte
CN100415725C (zh) *	2000-09-19	2008-09-03	住友化学工业株式会社	嘧啶类化合物及其用途
GB0112802D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112810D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0119477D0 (en)	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
ATE325115T1 (de)	2002-08-19	2006-06-15	Glaxo Group Ltd	Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
BRPI0406761A (pt)	2003-01-14	2005-12-20	Arena Pharm Inc	Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
AU2003222444A1 (en) *	2003-03-31	2004-10-25	Council Of Scientific And Industrial Research	NEW PYRIMIDINE LINKED PYRROLO(2,1-c)(1,4)BENZODIAZEPINES AS POTENTIAL ANTITUMOUR AGENTS
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS20060018A (en)	2003-07-14	2007-12-31	Arena Pharmaceuticals Inc.,	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US6966680B2 (en) *	2003-11-28	2005-11-22	Edward Kratz	Decorative lighting display with changeable shades and bulbs
CN1997640A (zh) *	2004-06-04	2007-07-11	艾尼纳制药公司	作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
NZ565898A (en) *	2005-09-16	2010-07-30	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) *	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
EP1941879A1 (de) *	2007-01-05	2008-07-09	PAION Deutschland GmbH	Nervenschutzmittel zur Behandlung von neuronalen Schäden.
DE102007051090A1 (de)	2007-06-28	2009-01-08	Charité - Universitätsmedizin Berlin	SSRI zur Behandlung neuronaler Krankheiten
EP2008653A1 (de)	2007-06-28	2008-12-31	Charité-Universitätsmedizin Berlin	Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten
EP4148045A1 (de)	2010-01-27	2023-03-15	Arena Pharmaceuticals, Inc.	Zwischenverbindungen zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon
AU2011305525B2 (en)	2010-09-22	2016-08-18	Arena Pharmaceuticals, Inc.	Modulators of the GPR119 receptor and the treatment of disorders related thereto
AU2016205361C1 (en)	2015-01-06	2021-04-08	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
IL285890B (en)	2015-06-22	2022-07-01	Arena Pharm Inc	Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
US11534424B2 (en)	2017-02-16	2022-12-27	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
EP3953762B1 (de) *	2019-04-09	2022-09-14	Gentex Corporation	Niedrig dimerisierende elektrochrome viologenverbindungen und vorrichtungen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3167553A (en) *	1963-05-08	1965-01-26	Searle & Co	2-amino-4-ethereal-5-methyl-6-phenylpyrimidines
BE756127A (fr) *	1969-09-12	1971-03-15	Hoechst Ag	Ethers heterocycliques et leur preparation
JPS4921148B1 (de) *	1970-12-28	1974-05-30
BE789099A (fr) *	1971-09-22	1973-03-21	Boehringer Sohn Ingelheim	Nouveaux derives de la pyridine et procede pour les fabriquer
US3937712A (en) *	1971-09-22	1976-02-10	Boehringer Ingelheim Gmbh	(5-nitro-2-furyl)-pyridines
US4115575A (en) *	1973-02-20	1978-09-19	Ciba-Geigy Corporation	2-(3-Amino-2-hydroxy-propoxy)-pyrazines
US4698340A (en) *	1984-07-19	1987-10-06	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) *	1984-10-01	1988-02-23	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine derivatives and composition of the same
WO1992004333A1 (en) *	1990-08-31	1992-03-19	Nippon Shinyaku Co., Ltd.	Pyrimidine derivative and medicine
US5294612A (en) *	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
IL117659A (en) *	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same

1995
- 1995-09-08 CN CN95195014A patent/CN1118454C/zh not_active Expired - Fee Related
- 1995-09-08 BR BR9508900A patent/BR9508900A/pt not_active IP Right Cessation
- 1995-09-08 MX MX9701765A patent/MX9701765A/es not_active IP Right Cessation
- 1995-09-08 DK DK95930725T patent/DK0781766T3/da active
- 1995-09-08 ES ES95930725T patent/ES2218552T3/es not_active Expired - Lifetime
- 1995-09-08 JP JP8509379A patent/JP3036079B2/ja not_active Expired - Fee Related
- 1995-09-08 DE DE69532811T patent/DE69532811T2/de not_active Expired - Fee Related
- 1995-09-08 US US08/809,004 patent/US5945426A/en not_active Expired - Fee Related
- 1995-09-08 EP EP95930725A patent/EP0781766B1/de not_active Expired - Lifetime
- 1995-09-08 AT AT95930725T patent/ATE263154T1/de not_active IP Right Cessation
- 1995-09-08 NZ NZ292269A patent/NZ292269A/en unknown
- 1995-09-08 RU RU97105769A patent/RU2128996C1/ru not_active IP Right Cessation
- 1995-09-08 PT PT95930725T patent/PT781766E/pt unknown
- 1995-09-08 CA CA002199518A patent/CA2199518A1/en not_active Abandoned
- 1995-09-08 HU HU9800853A patent/HU221855B1/hu not_active IP Right Cessation
- 1995-09-08 KR KR1019970701494A patent/KR100358245B1/ko not_active IP Right Cessation
- 1995-09-08 WO PCT/JP1995/001792 patent/WO1996007641A1/ja active IP Right Grant
1997
- 1997-03-07 NO NO19971050A patent/NO312995B1/no unknown
- 1997-03-07 FI FI970967A patent/FI970967A/fi unknown
1999
- 1999-06-16 US US09/334,253 patent/US6191149B1/en not_active Expired - Fee Related
- 1999-11-26 JP JP33560399A patent/JP3312616B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUT77779A (hu)	1998-08-28
FI970967A0 (fi)	1997-03-07
BR9508900A (pt)	1997-12-30
ATE263154T1 (de)	2004-04-15
EP0781766A1 (de)	1997-07-02
DE69532811T2 (de)	2005-03-17
KR100358245B1 (ko)	2003-11-28
KR970705545A (ko)	1997-10-09
MX9701765A (es)	1997-06-28
AU3399695A (en)	1996-03-27
DE69532811D1 (de)	2004-05-06
JP3036079B2 (ja)	2000-04-24
AU701395B2 (en)	1999-01-28
HU221855B1 (hu)	2003-02-28
WO1996007641A1 (fr)	1996-03-14
JP3312616B2 (ja)	2002-08-12
EP0781766B1 (de)	2004-03-31
US6191149B1 (en)	2001-02-20
EP0781766A4 (de)	1998-01-14
US5945426A (en)	1999-08-31
DK0781766T3 (da)	2004-07-26
FI970967A (fi)	1997-03-07
ES2218552T3 (es)	2004-11-16
PT781766E (pt)	2004-07-30
JP2000136184A (ja)	2000-05-16
NO971050D0 (no)	1997-03-07
RU2128996C1 (ru)	1999-04-20
NZ292269A (en)	1998-09-24
CA2199518A1 (en)	1996-03-14
CN1157609A (zh)	1997-08-20
CN1118454C (zh)	2003-08-20
NO971050L (no)	1997-05-09

Publication	Publication Date	Title
NO312995B1 (no)	2002-07-29	Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom
CZ295346B6 (cs)	2005-07-13	Pyrimidinové sloučeniny, způsob jejich přípravy, farmaceutická kompozice a jejich použití pro léčbu poruch souvisejících s ligandy dopaminu D3
ZA200502711B (en)	2006-07-26	Dihydropyridine compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
CA2000437A1 (en)	1990-04-20	2-azetidinone derivatives
EP3348547B1 (de)	2020-07-22	Benzimidazol-derivate als nav 1.7 (natriumkanal, spannungsgesteuerten, typ ix, alpha untereinheit (scn9a)) inhibitoren zur behandlung von schmerz, dysurie und multiple sclerose
WO1995031442A1 (en)	1995-11-23	Novel pyrimidine derivative
US6469168B1 (en)	2002-10-22	Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
JP4623354B2 (ja)	2011-02-02	新規ピリミジン誘導体及び新規ピリジン誘導体
JPH09241161A (ja)	1997-09-16	医薬
US6610717B2 (en)	2003-08-26	Dihydropyridine derivatives
FI88300B (fi)	1993-01-15	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara diazinylpiperidinderivat av cykliska amider och imider
US6855716B2 (en)	2005-02-15	Dihydropyrimidine compounds and compositions containing the same
KR0130646B1 (ko)	1998-04-10	이미다졸 부정맥증 치료제
US4663319A (en)	1987-05-05	3-(1,3-dithiol-2-ylidene)-2,4-dioxopyrrolidines, -piperidines, and -hexahydroazepines and use thereof against hepatic diseases
US5441948A (en)	1995-08-15	1,3,4-benzotraizepin-5(4H)-one derivatives and process for the preparation thereof
JP2815218B2 (ja)	1998-10-27	ピリミジンジオン誘導体、およびそれを含有する抗不整脈剤
JP2000154139A (ja)	2000-06-06	縮環ピラジン誘導体
CS276389B6 (en)	1992-05-13	Process for preparing derivatives of pyrimidinetrione
RU2775673C2 (ru)	2022-07-06	Новое соединение бензимидазола и его медицинское применение
CZ211399A3 (cs)	2000-09-13	1-fenylalkyl-1,2,3,6-tetrahydropyridiny pro léčení Alzheimerovy choroby
US5308848A (en)	1994-05-03	Pyrimidinedione derivatives and antiarrythmic agents containing the same
JPH06279373A (ja)	1994-10-04	アミノカルボン酸誘導体、その製造方法および用途